142 related articles for article (PubMed ID: 37978322)
1. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
Spyridonidis A; Labopin M; Gedde-Dahl T; Ganser A; Stelljes M; Craddock C; Wagner-Drouet EM; Versluis J; Schroeder T; Blau IW; Wulf GG; Dreger P; Olesen G; Sengeloev H; Kröger N; Potter V; Forcade E; Passweg J; de Latour RP; Maertens J; Wilson KMO; Bourhis JH; Finke J; Brissot E; Bazarbachi A; Giebel S; Savani BP; Nagler A; Ciceri F; Mohty M
Bone Marrow Transplant; 2024 Feb; 59(2):217-223. PubMed ID: 37978322
[TBL] [Abstract][Full Text] [Related]
2. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A; Labopin M; Savani BN; Niittyvuopio R; Blaise D; Craddock C; Socié G; Platzbecker U; Beelen D; Milpied N; Cornelissen JJ; Ganser A; Huynh A; Griskevicius L; Giebel S; Aljurf M; Brissot E; Malard F; Esteve J; Peric Z; Baron F; Ruggeri A; Schmid C; Gilleece M; Gorin NC; Lanza F; Shouval R; Versluis J; Bug G; Fløisand Y; Ciceri F; Sanz J; Bazarbachi A; Nagler A; Mohty M
Bone Marrow Transplant; 2020 Jun; 55(6):1114-1125. PubMed ID: 31996792
[TBL] [Abstract][Full Text] [Related]
3. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation.
Konuma T; Kanda J; Uchida N; Nishijima A; Tanaka M; Ozawa Y; Sawa M; Onizuka M; Ota S; Maruyama Y; Kanda Y; Kawakita T; Ara T; Eto T; Nakamae H; Kimura T; Fukuda T; Atsuta Y;
Hematol Oncol; 2023 Feb; 41(1):147-158. PubMed ID: 36268564
[TBL] [Abstract][Full Text] [Related]
4. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
7. Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study.
Fein JA; Shouval R; Galimard JE; Labopin M; Socié G; Finke J; Cornelissen JJ; Malladi R; Itälä-Remes M; Chevallier P; Orchard KH; Bunjes D; Aljurf M; Rubio MT; Versluis J; Mohty M; Nagler A
Blood Adv; 2023 May; 7(10):2143-2152. PubMed ID: 36622338
[TBL] [Abstract][Full Text] [Related]
8. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.
Manjappa S; Bhamidipati PK; Stokerl-Goldstein KE; DiPersio JF; Uy GL; Westervelt P; Liu J; Schroeder MA; Vij R; Abboud CN; Fehniger TA; Cashen AF; Pusic I; Jacoby M; Meera SJ; Romee R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):46-52. PubMed ID: 24120526
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
17. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Yegin ZA; Özkurt ZN; Dikyar A; Kaynar LA; Karacaoğlu Ö; Yağcı M
Transplant Proc; 2021; 53(6):2013-2020. PubMed ID: 34246474
[TBL] [Abstract][Full Text] [Related]
19. Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Houhou M; Caillot D; Finke J; Blaise D; Fegueux N; Ethell M; Cornelissen JJ; Forcade E; Yakoub-Agha I; Lussana F; Maertens J; Bourhis JH; Jindra P; Gorin NC; Nagler A; Mohty M
Bone Marrow Transplant; 2023 Apr; 58(4):393-400. PubMed ID: 36611097
[TBL] [Abstract][Full Text] [Related]
20. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
